Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price target of $175.00. The company’s shares ...

Johnson & Johnson (NYSE:JNJ) is reportedly shuttering its cardiovascular and metabolic drug unit as part of a restructuring of its pharmaceutical division. Impacted employees were notified on ...

A bankruptcy judge ruled on Thursday that Johnson & Johnson's third Chapter 11 case to resolve thousands of talcum powder ...

Of all the Biotech companies, Johnson & Johnson has one of the smoothest R&D lines that you will see, without many peaks or valleys. Their strong moat and ingrained cash flows allow the company to ...

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other blue chip stocks.

(RTTNews) - Johnson & Johnson (JNJ), Friday announced its decision to discontinue Phase 2 field study, evaluating the efficacy of Mosnodenvir, formerly JNJ-1802, for the prevention of dengue virus ...